HK Stock Market Move | QYUNS-B(02509) rose by over 6%, and internationalization of BD will be the company's core strategy this year. Sales of Sailexin are expected to reach 300 million yuan this year.

QYUNS-B(02509) rose more than 6%, reaching a high of HK$19.88, setting a new high since October last year, and the stock price has more than doubled so far this year. As of the time of writing, it has risen by 6.38% to HK$19.68, with a turnover of HK$5.7147 million. On the news front, in June of this year, Celltrion Bio held the second phase of investor research activities in Taizhou. It was mentioned that the company believes that products in the respiratory and IBD fields have the most potential for overseas expansion, as there is a high demand for treatment and existing therapies are not meeting the demand satisfactorily. Internationalization in the IBD field is a core strategy for the company this year, and it is actively laying out and promoting dual-antibody cooperation in the two key areas mentioned earlier. It is worth mentioning that in April of this year, Celltrion Bio announced a licensing agreement with Caldera Therapeutics. Caldera received exclusive global development and commercialization rights for QX030N, while Celltrion Bio received a one-time prepayment of $10 million, about 24.88% equity in Caldera, and up to an additional $545 million in milestone payments and sales net revenue tiered royalty fees under specific conditions. Celltrion Bio achieved revenue of RMB 159 million in 2024, with a net loss narrowing by 32.92% year-on-year. The company stated in its 2024 annual performance meeting that their biosimilar product, Selexin, has automatically entered the medical insurance catalog, and with the added strong sales capabilities of Huadong Medicine, it is expected that sales of the product in 2025 will reach RMB 300 million, with a peak of RMB 1.5-2 billion. After the product generates sales profits, the share obtained by Celltrion Bio will be included in the company's revenue.